Health
Press Release: PHARMAC opens consultation to address New Zealand’s biggest health issue1 – PRWire
Boehringer Ingelheim New Zealand welcomes a major PHARMAC proposal2 which could see up to 50,000 New Zealanders with type 2 diabetes and high risk of heart and kidney complications receive funded access to a medicine that not only lowers blood sugar, but
Boehringer Ingelheim New Zealand welcomes a major PHARMAC proposal2 which could see up to 50,000 New Zealanders with type 2 diabetes and high risk of heart and kidney complications receive funded access to a medicine that not only lowers blood sugar, but also reduces the risk of dying from heart complications.3,4
Under the new proposal, from 1December 2020, Jardiance (empagliflozin) would become the first and only oral diabetes medicine on New Zealands Pharmaceutical Schedule2 proven to deliver…
-
Business24 hours agoprofit up 7%, guidance strong
-
Noosa News17 hours agoKatter and pregnant wife crash-land plane in outback Qld
-
Noosa News17 hours agoFollowing Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’
-
Noosa News21 hours agoItalian Film Festival, Brisbane: All the Details